Johan Hansson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi request reprint Adjuvant therapy of cutaneous melanoma -- current status
    Johan Hansson
    Acta Oncol 45:369-72. 2006
  2. ncbi request reprint NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
    Esther Edlundh-Rose
    Department of Gene Technology, School of Biotechnology, Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
    Melanoma Res 16:471-8. 2006
  3. doi request reprint Familial melanoma
    Johan Hansson
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital Solna, S 17176 Stockholm, Sweden
    Surg Clin North Am 88:897-916, viii. 2008
  4. ncbi request reprint Familial cutaneous melanoma
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital Solna S 171 76, Stockholm, Sweden
    Adv Exp Med Biol 685:134-45. 2010
  5. pmc Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies
    Sara Raimondi
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ramusio 1, Milan, 20141, Italy
    BMC Med Res Methodol 12:116. 2012
  6. pmc A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
    Omid Hamid
    The Angeles Clinic and Research Institute, Santa Monica, USA
    J Transl Med 9:204. 2011
  7. doi request reprint Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Lancet Oncol 12:144-52. 2011
  8. ncbi request reprint Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
    J Clin Oncol 25:2819-24. 2007
  9. ncbi request reprint Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations
    Malihe Eskandarpour
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Hospital and Karolinska Institute, Stockholm, Sweden
    J Natl Cancer Inst 95:790-8. 2003
  10. doi request reprint MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
    Veronica Höiom
    Department of Oncology Pathology, CCK, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Pigment Cell Melanoma Res 22:196-204. 2009

Detail Information

Publications77

  1. ncbi request reprint Adjuvant therapy of cutaneous melanoma -- current status
    Johan Hansson
    Acta Oncol 45:369-72. 2006
  2. ncbi request reprint NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
    Esther Edlundh-Rose
    Department of Gene Technology, School of Biotechnology, Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
    Melanoma Res 16:471-8. 2006
    ..7). In conclusion, the separate genotypes were associated with differences in several key clinical and pathological parameters, indicating differences in the biology of melanoma tumours with different proto-oncogene mutations...
  3. doi request reprint Familial melanoma
    Johan Hansson
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital Solna, S 17176 Stockholm, Sweden
    Surg Clin North Am 88:897-916, viii. 2008
    ..Guidelines for management of familial melanoma and the issue of genetic testing for CDKN2A germline mutations are discussed...
  4. ncbi request reprint Familial cutaneous melanoma
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital Solna S 171 76, Stockholm, Sweden
    Adv Exp Med Biol 685:134-45. 2010
    ..A much smaller number of families have germline mutations in the CDK4 gene on chromosome 12q14, encoding a cyclin dependent kinase which normally interacts with p16INK4A. The management of families with hereditary melanoma is discussed...
  5. pmc Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies
    Sara Raimondi
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ramusio 1, Milan, 20141, Italy
    BMC Med Res Methodol 12:116. 2012
    ..Pooled-analysis of epidemiological studies has many advantages over meta-analysis, and preliminary results may be obtained faster and with lower costs than with prospective consortia...
  6. pmc A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
    Omid Hamid
    The Angeles Clinic and Research Institute, Santa Monica, USA
    J Transl Med 9:204. 2011
    ..The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab...
  7. doi request reprint Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Lancet Oncol 12:144-52. 2011
    ..We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma...
  8. ncbi request reprint Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program
    Johan Hansson
    Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
    J Clin Oncol 25:2819-24. 2007
    ..To evaluate a program initiated in 1987 by the Swedish Melanoma Study Group aiming to provide preventive surveillance to kindreds with hereditary cutaneous melanoma and dysplastic nevus syndrome...
  9. ncbi request reprint Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations
    Malihe Eskandarpour
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Hospital and Karolinska Institute, Stockholm, Sweden
    J Natl Cancer Inst 95:790-8. 2003
    ..We investigated the occurrence of NRAS mutations in melanomas and dysplastic nevi in individuals with germline CDKN2A mutations...
  10. doi request reprint MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
    Veronica Höiom
    Department of Oncology Pathology, CCK, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Pigment Cell Melanoma Res 22:196-204. 2009
    ..No association was found between CDKN2A gene variants and general melanoma risk. Two new variants in the POMC gene were identified in red haired individuals without RHC alleles...
  11. ncbi request reprint High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma
    Johan Falkenius
    aDepartment of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital bScience for Life Laboratory, Department of Gene Technology, Royal Institute of Technology, Stockholm, Sweden
    Melanoma Res 23:452-60. 2013
    ..011). Our results indicate that this prognostic panel in combination with established risk factors may contribute to an improved prediction of patients with a high risk of relapse...
  12. doi request reprint High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma
    Anders Jonsson
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet Karolinska University Hospital, Stockholm, Sweden
    J Invest Dermatol 130:2809-17. 2010
    ..Interestingly, p16(INK4A) promoter methylation was significantly overrepresented in NRAS-mutated samples compared to NRAS wild-type samples (P=0.0004), indicating an association between these two events...
  13. ncbi request reprint Non-invasive and microinvasive electrical impedance spectra of skin cancer - a comparison between two techniques
    Peter Aberg
    Division of Medical Engineering, Karolinska Institutet, Huddinge, Sweden
    Skin Res Technol 11:281-6. 2005
    ....
  14. ncbi request reprint NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
    Katarina Omholt
    Cancer Centre Karolinska, Department of Oncology Pathology, Radiumhemmet, Karolinska Hospital and Institute, Stockholm, Sweden
    Clin Cancer Res 9:6483-8. 2003
    ..Here, we have screened the same tumor samples for BRAF mutations...
  15. ncbi request reprint Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden
    Hanna Eriksson
    Hanna Eriksson, Eva Månsson Brahme, Margareta Frohm Nilsson, and Johan Hansson, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm Johan Lyth and Christer Lindholm, Regional Cancer Center Southeast, Linköping University Hospital Johan Lyth and John Carstensen, Linkoping University, Linköping Christian Ingvar, Lund University, Lund Peter Naredi, Sahlgrenska Academy and Ulrika Stierner, Sahlgrenska University Hospital, Gothenburg, Sweden
    J Clin Oncol 32:1356-64. 2014
    ..To investigate the association between cohabitation status, clinical stage at diagnosis, and disease-specific survival in cutaneous malignant melanoma (CMM)...
  16. ncbi request reprint Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
    Eva Grafström
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
    Clin Cancer Res 11:2991-7. 2005
    ..We have in the present study measured the frequency of INK4 deletions in a large number of melanoma metastases and determined their association with clinicopathologic variables and survival data...
  17. doi request reprint Hereditary uveal melanoma: a report of a germline mutation in BAP1
    Veronica Höiom
    Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
    Genes Chromosomes Cancer 52:378-84. 2013
    ..Such individuals may then be enrolled in preventive programs and regular screenings to facilitate early detection and thereby improve prognosis...
  18. doi request reprint Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
    Anton Platz
    Department of Oncology Pathology, Karolinska Institute, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm S 17176, Sweden
    Mol Oncol 1:395-405. 2008
    ..Common alterations of the signal transducing network seem to represent molecular hallmarks of cutaneous melanomas and therefore should continue to strongly stimulate design and testing of targeted molecular interventions...
  19. doi request reprint Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
    Yvonne Brandberg
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Acta Oncol 52:1086-93. 2013
    ..To investigate the role of health-related quality of life (HRQoL) at randomization as independent prognostic factors for survival and time to failure, and to explore associations between HRQoL and treatment effects...
  20. doi request reprint Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma
    Braslav Jovanovic
    Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    J Invest Dermatol 128:2696-704. 2008
    ..Immunohistochemical analysis of cytoplasmic phosphorylated ERK could be used as a prognostic marker in primary melanomas if confirmed in another data set...
  21. ncbi request reprint Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
    Giuseppe Valentino Masucci
    Department of Oncology Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
    Melanoma Res 16:357-63. 2006
    ..Thrombocytopenia might be a positive predictive factor for response to therapy...
  22. doi request reprint Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study
    Mia Bergenmar
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital, SE 17176 Stockholm, Sweden
    Eur J Oncol Nurs 13:74-80. 2009
    ..The aim was to prospectively explore experiences related to genetic testing for malignant melanoma among unaffected previously untested members of melanoma-prone families in which germline CDKN2A mutations had been identified...
  23. doi request reprint Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
    C Christian Johansson
    Department of Oncology and Pathology, Cancer Center Karolinska, R8 01, Karolinska University Hospital, Karolinska Institutet, 171 76 Stockholm, Sweden
    Cancer Immunol Immunother 58:1085-94. 2009
    ..The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma...
  24. doi request reprint Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
    Malihe Eskandarpour
    Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Int J Cancer 124:16-26. 2009
    ..These studies support the concept that suppression of oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by modulating the levels of these gene products...
  25. ncbi request reprint Mutations of PIK3CA are rare in cutaneous melanoma
    Katarina Omholt
    Department of Oncology Pathology, Cancer Centre Karolinska, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
    Melanoma Res 16:197-200. 2006
    ..Taken together, our results show that PIK3CA is mutated in a minority of melanomas and suggest that mutations in this gene may represent an alternative mechanism of Akt activation in cutaneous melanoma...
  26. ncbi request reprint The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
    Hildur Helgadottir
    Department of Oncology Pathology, Karolinska Institute, Radiumhemmet, Karolinska University Hospital, 171 76, Stockholm, Sweden
    Cancer Immunol Immunother 58:1599-608. 2009
    ..1 [(A2) B15 Cw3 DRB1*04] in patients with stage III-IV serous ovarian cancer. The objective of the present study was to determine the role of the HLA phenotype on the prognosis in stage III-IV malignant melanoma patients...
  27. ncbi request reprint Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma
    Peter Berg
    Department of Dermatology and Venereology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden
    Melanoma Res 14:251-5. 2004
    ..Thus, in the large majority of cutaneous melanoma in childhood/adolescence, any underlying genetic alterations have yet to be identified...
  28. doi request reprint MicroRNA expression profiles associated with mutational status and survival in malignant melanoma
    Stefano Caramuta
    Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    J Invest Dermatol 130:2062-70. 2010
    ..The identification of an miRNA classifier for poor survival may lead to the development of miRNA detection as a complementary prognostic tool in clinical practice...
  29. doi request reprint Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management
    Hanna Eriksson
    Department of Medicine, Unit of Dermatology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Acta Derm Venereol 93:411-6. 2013
    ..In conclusion, review by a pathologist experienced in melanoma resulted in a change in recommendations about surgical excision margins and/or sentinel node biopsy in subgroups of T1 melanomas...
  30. doi request reprint Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms
    Yumeng Mao
    Cancer Center Karolinska, Institution of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
    Cancer Res 73:3877-87. 2013
    ..In summary, our results reveal how immune suppression by MDSC can be initiated in the tumor microenvironment of human melanoma...
  31. ncbi request reprint Implementing organisation and management innovations in Swedish healthcare: lessons from a comparison of 12 cases
    John Øvretveit
    The Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    J Health Organ Manag 26:237-57. 2012
    ....
  32. ncbi request reprint Investigation of a putative melanoma susceptibility locus at chromosome 3q29
    Rainer Tuominen
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
    Cancer Genet 207:70-4. 2014
    ..Sequencing of genes in the region may identify novel melanoma-associated mutations. ..
  33. ncbi request reprint KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
    Abdlsattar Zebary
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden Electronic address
    J Dermatol Sci 72:284-9. 2013
    ..Although the involvement of KIT, NRAS and BRAF mutations is well known in ALM, the impact of these mutations on clinicopathological features has not been established...
  34. doi request reprint Case study of how successful coordination was achieved between a mental health and social care service in Sweden
    Johan Hansson
    LIME, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Int J Health Plann Manage 27:e132-45. 2012
    ..One lesson for the current policy is that, where full structural integration is not possible, then client-level coordination roles in each sector are useful to connect sector services for shared clients...
  35. doi request reprint Genome-wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanoma
    Veronica Höiom
    Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, S 171 76 Stockholm, Sweden
    Genes Chromosomes Cancer 50:1076-84. 2011
    ..01). Our data suggest that these chromosomal regions, 17p12-p11 in particular as it was present in both analyses, may harbor genes involved in the susceptibility of malignant melanoma in the Swedish population...
  36. ncbi request reprint High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics
    Andreas Ekborn
    Department of Otolaryngology Head and Neck Surgery, Karolinska Institute, Stockholm, Sweden
    Laryngoscope 114:1660-7. 2004
    ....
  37. ncbi request reprint Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression
    Katarina Omholt
    Cancer Centre Karolinska, Department of Oncology Pathology, Radiumhemmet, Karolinska Hospital and Institute, Stockholm, Sweden
    Clin Cancer Res 8:3468-74. 2002
    ..This study was aimed to measure the frequency of such mutations in a large series of paired primary and metastatic melanomas to determine their role in melanoma initiation and progression...
  38. ncbi request reprint Simulation team training for improved teamwork in an intensive care unit
    Christer Sandahl
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    Int J Health Care Qual Assur 26:174-88. 2013
    ..This study aims to describe implementation of simulator-based medical team training and the effect of this programme on inter-professional working in an intensive care unit (ICU)...
  39. ncbi request reprint Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
    Malihe Eskandarpour
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
    Int J Cancer 115:65-73. 2005
    ..These data suggest that oncogenic NRAS is important for avoidance of apoptosis in melanomas that harbor the codon 61 NRAS mutation and emphasizes oncogenic NRAS as a therapeutic target in patients with tumors that harbor this mutation...
  40. ncbi request reprint Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex)
    Boel Ragnarsson-Olding
    Department of Oncology, Radiumhemmet, Karolinska University Hospital Solna, Stockholm, Sweden
    Acta Oncol 44:773-7. 2005
  41. ncbi request reprint Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma
    Mia Bergenmar
    Department of Oncology Pathology, Karolinska Hospital and Institutet, Stockholm, Sweden
    Acta Oncol 43:161-8. 2004
    ....
  42. ncbi request reprint Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign
    Isabel Poschke
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden
    Cancer Res 70:4335-45. 2010
    ..These results emphasize the diversity of MDSC in human cancer and provide potential targets for therapeutic interventions...
  43. ncbi request reprint Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial
    Mia Bergenmar
    Department of Oncology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Scand J Plast Reconstr Surg Hand Surg 44:146-55. 2010
    ..No differences in health-related QoL or emotional distress were found between the two arms, indicating that resection margins have limited impact on these variables...
  44. ncbi request reprint A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF
    Jamileh Hashemi
    Department of Oncology Pathology, Research Laboratory of Radiumhemmet, Cancer Center Karolinska, R8 03, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Cancer Lett 180:211-21. 2002
    ..This partial functional defect may complement the clearly defective p16 del (62-69) mutant and thus contribute to melanoma development in patients carrying the 24bp deletion in CDKN2A...
  45. ncbi request reprint Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing
    Max Käller
    Department of Biotechnology, The Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
    Clin Chem 51:2388-91. 2005
  46. ncbi request reprint Context challenges the champion: improving hip fracture care in a Swedish university hospital
    Susanne Löfgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Int J Health Care Qual Assur 25:118-33. 2012
    ..The purpose of this paper is to describe and explain a clinician-led improvement of a hip fracture care process in a university hospital, and to assess the results and factors helping and hindering change implementation...
  47. doi request reprint KIT pathway alterations in mucosal melanomas of the vulva and other sites
    Katarina Omholt
    Department of Oncology Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Clin Cancer Res 17:3933-42. 2011
    ....
  48. doi request reprint Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts
    Jessica Cedervall
    Department of Woman and Child Health, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Cancer Res 69:3746-54. 2009
    ..In conclusion, these data provide exciting options for using the hEST model in molecular in vivo studies on differentiation, invasiveness, and malignancy of human melanoma, while analyzing species-specific reactions in vivo...
  49. ncbi request reprint Surgical treatment of skeletal metastases in 31 melanoma patients
    Rikard Wedin
    Dept of Orthopaedics, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Acta Orthop Belg 78:246-53. 2012
    ..This study represents the largest reported cohort surgically treated for skeletal metastasis of malignant melanoma at a single institution...
  50. doi request reprint What happened to the no-wait hospital? A case study of implementation of operational plans for reduced waits
    Johan Hansson
    Department of Learning Informatics Management and Ethics, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Qual Manag Health Care 21:34-43. 2012
    ..This article reports a case study of a hospital implementation of operational plans for reduced waits, with an emphasis on the process of change...
  51. ncbi request reprint No evidence of RALGDS mutations in cutaneous melanoma
    Katarina Omholt
    Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Melanoma Res 17:410-2. 2007
  52. ncbi request reprint Integrated molecular portrait of non-small cell lung cancers
    Vladimir Lazar
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    BMC Med Genomics 6:53. 2013
    ..The objectives of this study were to utilize integrated genomic data including copy-number alteration, mRNA, microRNA expression and candidate-gene full sequencing data to characterize the molecular distinctions between AC and SCC...
  53. doi request reprint Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study
    Therese M L Andersson
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden Electronic address
    Cancer Epidemiol 38:93-9. 2014
    ..This group of patients is referred to as the cure proportion. Few studies have examined the possibility of cure for CMM. The aim of this study was to estimate the cure proportion of patients with CMM in a Swedish population...
  54. ncbi request reprint Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling
    Aleksandra Mandic
    Department of Oncology Pathology, CancerCenterKarolinska, Karolinska Institute and Hospital, S 171 76 Stockholm, Sweden
    J Biol Chem 278:9100-6. 2003
    ..We have thus identified a novel mechanism of action of cisplatin. The results have implications for the understanding of resistance mechanisms as well as the unique efficiency of this drug...
  55. ncbi request reprint Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
    Shuhua Ma
    Department of Oncology Pathology, Research Laboratory of Radiumhemmet, Cancer Centre Karolinska, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Oncol Rep 9:1015-9. 2002
    ..However, there was no significant correlation of MMR expression alone or combined with MGMT levels with clinical response to DTIC-based chemotherapy in metastatic melanoma...
  56. ncbi request reprint Skin cancer identification using multifrequency electrical impedance--a potential screening tool
    Peter Aberg
    Division of Medical Engineering, Karolinska Institutet, Novum Research Park, SE 14186 Huddinge, Sweden
    IEEE Trans Biomed Eng 51:2097-102. 2004
    ..The power of skin cancer detection using electrical impedance is as good as, or better than, conventional visual screening made by general practitioners...
  57. pmc Suffering in silence: a qualitative study of second victims of adverse events
    Susanne Ullström
    Department of Learning, Informatics, Management and Ethics LIME, Medical Management Centre MMC, Karolinska Institutet, Stockholm, Sweden
    BMJ Qual Saf 23:325-31. 2014
    ..The aim of this study was to investigate how healthcare professionals are affected by their involvement in adverse events with emphasis on the organisational support they need and how well the organisation meets those needs...
  58. pmc Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers
    Tord Forsner
    Department of Public Health Sciences, Karolinska Institutet, Stockholm SE 171 76, Sweden
    BMC Psychiatry 10:8. 2010
    ..The aim of this study was to determine perceived facilitators and barriers to guideline implementation and clinical compliance to guidelines for depression in psychiatric care...
  59. doi request reprint Melanoma cells produce multiple laminin isoforms and strongly migrate on α5 laminin(s) via several integrin receptors
    Yuko Oikawa
    Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
    Exp Cell Res 317:1119-33. 2011
    ....
  60. doi request reprint An integrated health and social care organisation in Sweden: creation and structure of a unique local public health and social care system
    John Øvretveit
    The Medical Management Centre, Karolinska Institute, Sweden
    Health Policy 97:113-21. 2010
    ....
  61. ncbi request reprint FBXW7/hCDC4 is a general tumor suppressor in human cancer
    Shahab Akhoondi
    Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Cancer Res 67:9006-12. 2007
    ..Our study is the first comprehensive screen of FBXW7 mutations in various human malignancies and shows that FBXW7 is a general tumor suppressor in human cancer...
  62. pmc Common sequence variants on 20q11.22 confer melanoma susceptibility
    Kevin M Brown
    Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona 85028, USA
    Nat Genet 40:838-40. 2008
    ..The per allele odds ratio was 1.75 (1.53, 2.01), with evidence for stronger association in early-onset cases...
  63. doi request reprint ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma
    Daniel F Gudbjartsson
    deCODE Genetics, Sturlugata 8, 101 Reykjavik, Iceland
    Nat Genet 40:886-91. 2008
    ..14, P = 6.1 x 10(-4)). An eye color variant in TYRP1 was associated with risk of CM (OR = 1.15, P = 4.6 x 10(-4)). The association of all three variants is robust with respect to adjustment for the effect of pigmentation...
  64. ncbi request reprint Genetic testing for melanoma
    Richard Kefford
    Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, New South Wales, 2145, Australia
    Lancet Oncol 3:653-4. 2002
  65. ncbi request reprint High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL
    Alisa M Goldstein
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
    Cancer Res 66:9818-28. 2006
    ..This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available...
  66. ncbi request reprint A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women
    Marit Bragelien Veierød
    Section of Medical Statistics, University of Oslo, Oslo, Norway
    J Natl Cancer Inst 95:1530-8. 2003
    ..Here we report the first results from a large prospective cohort study of pigmentation factors and sun exposure in relation to melanoma risk...
  67. ncbi request reprint Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations
    Peter Gillgren
    Department of Surgery, Stockholm Soder Hospital, SE 118 83 Stockholm, Sweden
    Melanoma Res 15:125-32. 2005
    ..It can be concluded that the tumour site is of prognostic importance, and that the middle and lower back and supramammary and mammary areas are independent factors related to a poor prognosis...
  68. pmc Localization of a novel melanoma susceptibility locus to 1p22
    Elizabeth Gillanders
    Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    Am J Hum Genet 73:301-13. 2003
    ..43, was obtained at D1S2779 and occurred when the 15 families with the earliest ages at onset were included. These data provide significant evidence of a novel susceptibility gene for CMM located within chromosome band 1p22...
  69. ncbi request reprint Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients
    Paola Ghiorzo
    Department of Oncology, Biology, and Genetics, University of Genova, Genova, Italy
    Hum Pathol 35:25-33. 2004
    ....
  70. ncbi request reprint Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors
    Christer Lindholm
    Department of Oncology, County Hospital Ryhov, Jonkoping, Sweden
    Cancer 101:2067-78. 2004
    ....
  71. ncbi request reprint Geographical variation in the penetrance of CDKN2A mutations for melanoma
    D Timothy Bishop
    Genetic Epidemiology Division, Cancer Research UK Clinical Centre, St James s University Hospital, Leeds, UK
    J Natl Cancer Inst 94:894-903. 2002
    ..We examined the penetrance of such mutations using data from eight groups from Europe, Australia and the United States that are part of The Melanoma Genetics Consortium...
  72. doi request reprint Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVB
    Jean Emeny
    Department of Biochemistry, University of Leicester, United Kingdom
    J Invest Dermatol 128:1875-7. 2008
  73. ncbi request reprint Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B
    Carola Berking
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    Cancer Res 64:807-11. 2004
    ..This is the first report on human cancer initiation in vivo in which an imbalance of physiological factors combined with an environmental carcinogen can lead to transformation of normal tissue...
  74. pmc Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents
    Alisa M Goldstein
    Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, Maryland 20892 7236, USA
    J Med Genet 44:99-106. 2007
    ....
  75. ncbi request reprint The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma
    Micaela Hernberg
    Department of Oncology, HUSLAB, Helsinki University Central Hospital, Finland
    J Immunother 30:773-9. 2007
    ..Our data show that both the proportions of CD3+CD4+CD69+ cells and of CD3+CD56+ cells seem to have a prognostic potential in the natural course of melanoma. These results need to be confirmed in larger studies...
  76. pmc Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
    Keiran S M Smalley
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Mol Cancer Ther 7:2876-83. 2008
    ....
  77. ncbi request reprint Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases
    Asa Sivertsson
    AlbaNova University Center, Department of Molecular Biotechnology, Royal Institute of Technology KTH, S 106 91 Stockholm, Sweden
    Clin Chem 48:2164-70. 2002
    ..We evaluated pyrosequencing, a simple and rapid method used mainly for single-nucleotide polymorphism analysis, as a possible alternative to single-strand conformation polymorphism (SSCP) analysis and sequencing of N-ras...